Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

82. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonasaeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patientswith cystic fibrosis. Antimicrob Agent Chemother 2002;46:1105–7.83. Nicodemo AC, Araujo MR, Ruiz AS, Gales AC. In vitro susceptibility of Stenotrophomonas maltophilia isolates:comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother 2004;53:604–8.84. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis:prevalence and clinical relevance. J Cyst Fibros 2007;6:75–8.85. Tan K, Conway SP, Brownlee KG, Etherington C, Peckham DG. Alcaligenes infection in cystic fibrosis. PediatrPulmonol 2002;34:101–4.86. Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F. Microbiology of airway disease in a cohort ofpatients with cystic fibrosis. BMC Infect Dis 2006;6:4.87. Ronne HC, Pressler T, Hoiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosispatients; a retrospective case control study. J Cyst Fibros 2006;5:245–51.88. Ronne HC, Pressler T, Hoiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosispatients; a retrospective case control study. J Cyst Fibros 2006;5:245–51.89. Van Daele S, Verhelst R, Claeys G, Verschraegen G, Franckx H, Van Simaey L et al. Shared genotypes ofAchromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol2005;43:2998–3002.90. Tan K, Conway SP, Brownlee KG, Etherington C, Peckham DG. Alcaligenes infection in cystic fibrosis. PediatrPulmonol 2002;34:101–4.91. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis:prevalence and clinical relevance. J Cyst Fibros 2007;6:75–8.92. Ronne HC, Pressler T, Hoiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosispatients; a retrospective case control study. J Cyst Fibros 2006;5:245–51.93. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z et al. Identification and antimicrobial susceptibility ofAlcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2001;39:3942–5.94. Segonds C, Paute S, Chabanon G. Use of amplified ribosomal DNA restriction analysis for identification ofRalstonia and Pandoraea sp.: interest in determination of the respiratory bacterial flora in patients with cysticfibrosis. J Clin Microbiol 2003;41:3415–8.95. Jorgensen IM, Johansen HK, Frederiksen B, Pressler T, Hansen A, Vandamme P et al. Epidemic spread ofPandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol2003;36:439–46.96. Johnson LN, Han JY, Moskowitz SM, Burns JL, Qin X, Englund JA. Pandoraea bacteremia in a cystic fibrosispatient with associated systemic illness. Pediatr Infect Dis J 2004;23:881–2.97. Atkinson RM, LiPuma JJ, Rosenbluth DB, Dunne WM, Jr. Chronic colonization with Pandoraea apista in cysticfibrosis patients determined by repetitive-element-sequence PCR. J Clin Microbiol 2006;44:833–6.98. Johnson LN, Han JY, Moskowitz SM, Burns JL, Qin X, Englund JA. Pandoraea bacteremia in a cystic fibrosispatient with associated systemic illness. Pediatr Infect Dis J 2004;23:881–2.99. Atkinson RM, LiPuma JJ, Rosenbluth DB, Dunne WM, Jr. Chronic colonization with Pandoraea apista in cysticfibrosis patients determined by repetitive-element-sequence PCR. J Clin Microbiol 2006;44:833–6.100. Wat D,.Doull I. Respiratory virus infections in cystic fibrosis. Paediatr Respir Rev 2003;4:172–7.101. Matheson NJ, Hardnen AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors forpreventing and treating influenza in children. Cochrane Database Syst Rev 2007;Issue 1. Art. No.: CD002744.DOI: 10.1002/14651858.CD002744.pub2.102. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitorsin treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlledtrials. BMJ 2003;326:1235.103. National Institute for Clinical Effectiveness. Flu treatment - zanamivir (review), amantadine, and oseltamivir.London: NICE, 2003.104. Dharmaraj P, Tan A, Smyth R. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane DatabaseSyst Rev 2000;Issue 1. Art. No.: CD001753. DOI: 10.1002/14651858.CD001753.105. Malfroot A, Adam G, Ciofu O, Doring G, Knoop C, Lang AB et al. Immunisation in the current management ofcystic fibrosis patients. J Cyst Fibros 2005;4:77–87.106. Rodgers HC, Liddle K, Nixon SJ, Innes JA, Greening AP. Totally implantable venous access devices in cysticfibrosis: complications and patients’ opinions. Eur Respir J 1998;12:217–20.Cystic Fibrosis Trust 7.10March 2009